CCR5 and cancer: These results, together, demonstrate that αPD-L1-γδ T cells not only possess improved cytotoxicity toward PD-L1-positive cancer cells, but also fine-tuned the TME, at least partially via the CCR5/CCL5 axis (Fig. 6m).